155 results
Page 4 of 8
8-K
EX-99.2
fh40nworl1gkrtjkaek
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
nlumhwf64cxad
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K/A
EX-99.3
h0he8i
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.1
icc nwvq52cli
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.2
u9ov0yx
23 Nov 20
Consolidated Financial Statements
12:00am
8-K
EX-99.1
zsqkpr7 1rtfa76w
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K
EX-10.3
fknypv fn0xor9q
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
424B3
1ajz6jssn7lhcx
28 Aug 20
Prospectus supplement
4:31pm
8-K
EX-99.1
36s8ph5
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
425
10qvs4o
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-10.1
fdaupgzqffoybcxa3e
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-2.1
npvt5r7pln37
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
425
oqomz2k2
24 Jun 20
Business combination disclosure
4:03pm